Greg Divis, Avadel CEO

Lit­tle biotech makes deep cuts as it strug­gles to get nar­colep­sy drug ap­proved amid months of reg­u­la­to­ry lim­bo

Be­lea­guered by mul­ti­ple de­lays, Avadel Phar­ma­ceu­ti­cals is pulling out all the stops to try and clinch an FDA ap­proval for its nar­colep­sy drug faster. But …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.